Efficacy and safety results from comparison of alemtuzumab and Rebif® efficacy in multiple sclerosis II (CARE-MS II): A phase 3 study in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy

Authors
Category Primary study
ConferenceNeurology
Year 2012
This article has no abstract
Epistemonikos ID: e01b25a74996b3a40525d8af3cf051be8f786b30
First added on: Apr 30, 2026